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Abstract 
Increased liver fat may be caused by insulin resistance and adipose tissue inflamma-
tion or by the common I148M variant in PNPLA3 at rs738409, which lacks both of these 
features. We hypothesized that obesity/insulin resistance rather than liver fat increases 
circulating coagulation factor activities. We measured plasma prothrombin time (PT, 
Owren method), activated partial thromboplastin time (APTT), activities of several co-
agulation factors, VWF:RCo and fibrinogen, and D-dimer concentration in 92 subjects 
divided into groups based on insulin sensitivity [insulin-resistant (‘IR’) vs. insulin-sen-
sitive (‘IS’)] and PNPLA3 genotype (PNPLA3148MM/MI vs. PNPLA3148II). Liver fat content 
(1H-MRS) was similarly increased in ‘IR’ (13±1%) and PNPLA3148MM/MI (12±2%) as 
compared to ‘IS’ (6±1%, p<0.05) and PNPLA3148II (8±1%, p<0.05), respectively. FVIII, 
FIX, FXIII, fibrinogen and VWF:RCo activities were increased, and PT and APTT short-
ened in ‘IR’ vs. ‘IS’, in contrast to these factors being similar between PNPLA3148MM/MI 
and PNPLA3148II groups. In subjects undergoing a liver biopsy and entirely lacking the 
I148M variant, insulin-resistant subjects had higher hepatic expression of F8, F9 and 
FGG than equally obese insulin-sensitive subjects. Expression of pro-inflammatory 
genes in adipose tissue correlated positively with PT (% of normal), circulating FVIII, 
FIX, FXI, VWR:RCo and fibrinogen, and expression of anti-inflammatory genes nega-
tively with PT (%), FIX and fibrinogen. We conclude that obesity/insulin resistance ra-
ther than an increase in liver fat is associated with a procoagulant plasma profile. This 
reflects adipose tissue inflammation and increased hepatic production of coagulation 
factors and their susceptibility for activation.  
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Abbreviations 
36B4  acidic ribosomal phosphoprotein 36B4 
ALT  alanine aminotransferase 
APTT  activated partial thromboplastin time 
AST   aspartate aminotransferase 
BMI  body mass index 
CD68  cluster of differentiation 68 
CVD  cardiovascular disease 
HDL  high-density lipoprotein 
1H-MRS  proton magnetic resonance spectroscopy 
HOMA-IR  homeostatic model assessment of insulin resistance 
IR  insulin-resistant 
IS  insulin-sensitive 
LDL  low-density lipoprotein 
MCP-1  monocyte chemoattractant protein 1 
NAFLD  non-alcoholic fatty liver disease 
PNPLA3  patatin-like phospholipase domain-containing 3 
PT  prothrombin time 
SDHA   succinate dehydrogenase complex, subunit A 
TNF-α  tumor necrosis factor alpha 
Twist1  Twist-related protein 1 
VWF  von Willebrand factor 
VWF:RCo  von Willebrand factor ristocetin cofactor activity 
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Introduction 
Recent studies have shown that non-alcoholic fatty liver disease (NAFLD) is heteroge-
neous [1]. Insulin resistance, obesity and systemic low-grade inflammation character-
ise ‘Metabolic NAFLD’ and predispose to type 2 diabetes, venous thrombosis and car-
diovascular disease (CVD)  [2,3]. A common gene variant with a worldwide prevalence 
of 30-50% in the patatin-like phospholipase domain-containing 3 gene (PNPLA3) 
(rs738409; C>G/I148M) increases the risk of NAFLD, independently of obesity  [4]. It 
increases liver fat in both humans and animal models but does not alter insulin sensi-
tivity  [4-6]. Thus, carriers of the I148M gene variant are neither more obese nor do 
they have changes in glucose or insulin concentrations or inflammation in adipose tis-
sue  [7,8]. The latter seems critical for the development of insulin resistance in the liver  
[9-11]. NAFLD caused by the I148M variant does not associate with an increased risk 
of diabetes or CVD [2].  
 
Hepatocytes or sinusoidal endothelial cells in the liver are major sites of production of 
coagulation factors  [12,13]. In NAFLD, activities of coagulation factors such as FVII  
[14], FVIII  [15], FIX  [15], FXI  [15], FXII  [15], von Willebrand factor (VWF) [15,16] and 
fibrinogen  [15,16] are all increased. These changes augment the risk of venous throm-
bosis and of atherothrombotic vascular disease  [17,18]. It is, however, unknown 
whether the increase in coagulation factors in NAFLD is due to obesity/insulin re-
sistance and associates with adipose tissue inflammation or due to increased liver fat 
content per se. NAFLD caused by the PNPLA3 I148M variant thus provides a model 
in which steatosis can be dissociated from obesity/insulin resistance. Coagulation fac-
tor activities have not been studied in different types of NAFLD.  
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The mechanisms underlying increased activities of coagulation factors in NAFLD are 
unclear. Expression of coagulation factors in the human liver has not been compared 
between insulin resistant and sensitive subjects. Adipose tissue in insulin-resistant 
subjects over-expresses pro-inflammatory cytokines and chemokines, but shows de-
creased expression of anti-inflammatory adipokines  [9,19-21]. These changes impair 
insulin action, such as regulation of platelet-collagen interaction  [22], and stimulate 
synthesis of hepatic acute phase reactants and coagulation factors, such as fibrinogen, 
FVIII, and FXIII  [23-25].  
 
In the present study, we hypothesized that i) coagulation factor activities are higher in 
subjects with increased liver fat content associated with obesity/insulin resistance than 
in subjects with increased liver fat content due to PNPLA3 I148M variant, ii) coagula-
tion factor production as judged from hepatic expression is upregulated in insulin-re-
sistant subjects with excessive liver fat, and iii) adipose tissue inflammation correlates 
with circulating coagulation factor activities. To this end, we studied, in representative 
groups of subjects, circulating coagulation factor activities, their expression in liver bi-
opsies and expression of pro- and anti-inflammatory cytokines/chemokines in biopsies 
of adipose tissue. 
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Methods 
Subjects and study designs 
Circulating coagulation factor activities. To examine the impact of the PNPLA3 I148M 
variant on plasma coagulation factors, we recruited 92 subjects based on the following 
inclusion criteria: i) age 18 to 75 years; ii) no known acute or chronic disease except 
for obesity, hypertension, or NAFLD based on medical history, physical examination 
and standard laboratory tests (complete blood count, serum creatinine, thyroid-stimu-
lating hormone, sodium and potassium concentrations) and ECG; iii) alcohol consump-
tion less than 20 g per day in women and less than 30 g per day for men. None of the 
study subjects had type 2 diabetes. The subjects were divided based on their PNPLA3 
genotype at rs738409 into those with (PNPLA3148MM/MI) and without (PNPLA3148II) the 
I148M variant. The subjects were also divided based on median homeostatic model 
assessment of insulin resistance (HOMA-IR) into insulin-resistant ‘IR’ and insulin-sen-
sitive ‘IS’ groups. Clinical characteristics of these groups are shown in Table 1. 
 
Since both obesity/insulin resistance and the PNPLA3 I148M variant are common, we 
also analyzed coagulation factors in a 2 by 2 fashion in four subgroups of subjects who 
had both risk factors, i.e. both insulin resistance and the I148M variant (‘double trouble’ 
i.e. ‘IR and PNPLA3148MM/MI’), one risk factor, i.e. either insulin resistance without the 
gene variant (‘single trouble IR’ i.e. ‘IR and PNPLA3148II’) or carried the PNPLA3 I148M 
variant without insulin resistance (’single trouble PNPLA3148MM/MI’ i.e. ‘IS and 
PNPLA3148MM/MI’), or had neither risk factor (‘IS and PNPLA3148II’). Clinical characteris-
tics are shown in Supplementary Table 1. 
 
Gene expression of coagulation factors in the human liver. We determined whether 
changes in circulating coagulation factors in insulin-resistant subjects with increased 
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liver fat content but lacking PNPLA3 I148M gene variant were due to changes in their 
hepatic expression. For that purpose, we recruited consecutive subjects undergoing 
bariatric surgery, in whom a liver biopsy was clinically indicated. Inclusion criteria were: 
i) age 18 to 65 years; ii) no known acute or chronic disease, except for obesity, hyper-
tension, NAFLD or type 2 diabetes based on medical history, physical examination, 
standard laboratory tests (complete blood count, serum creatinine, thyroid-stimulating 
hormone, sodium and potassium concentrations) and ECG; iii) daily alcohol consump-
tion less than 20 g in women and less than 30 g for men; (iv) no history of use of toxins 
or drugs influencing liver steatosis; and (v) no use of any anticoagulant drugs. 
 
The subjects were invited to a separate clinical visit one week prior to surgery for de-
tailed metabolic characterization. They came to the clinical research centre after an 
overnight fast. Body weight, height, body mass index (BMI), waist circumference and 
blood pressure were measured. An intravenous cannula was inserted in an antecubital 
vein for collection of blood to measure glycosylated haemoglobin A1c (HbA1c), serum 
insulin, plasma glucose, low-density lipoprotein (LDL) and high-density lipoprotein 
(HDL) cholesterol, triglyceride, aspartate aminotransferase (AST) and alanine ami-
notransferase (ALT) concentrations, and for genotyping of PNPLA3 at rs738409. After 
basal blood sampling and anthropometric measurements, a 75-g oral glucose toler-
ance test was performed, during which both glucose and insulin concentrations at 0, 
30 and 120 min were captured. HOMA-IR was used as a proxy for insulin resistance  
[26]. The Matsuda insulin sensitivity index was applied as another measure of insulin 
sensitivity and was calculated from insulin and glucose concentrations assessed at 0, 
30 and 120 minutes during the oral glucose tolerance test  [27]. After genotyping con-
secutive patients, we identified 26 subjects lacking the PNPLA3 I148M gene variant 
(PNPLA3148II), who were divided into those with ‘Metabolic NAFLD’ and without NAFLD 
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(‘No NAFLD’) based on % of hepatocytes with macroscopic steatosis in the liver biop-
sies (see below).  
 
Adipose tissue inflammation. To determine whether coagulation factor activities are 
associated with pro- or anti-inflammatory cytokines or adipokines in subjects lacking 
the gene variant i.e. in PNPLA3148II subjects, we obtained needle biopsies of adipose 
tissue from the abdominal region and measured coagulation factor activities in 26 such 
subjects  [8]. Gene expression of pro-inflammatory markers [the macrophage marker 
cluster of differentiation 68 (CD68), monocyte chemoattractant protein 1 (MCP-1) and 
tumor necrosis factor alpha (TNF-α)] and of anti-inflammatory markers [ADIPOQ and 
Twist-related protein-1 (TWIST1)] were measured in the adipose tissue biopsies, and 
serum MCP-1 and adiponectin concentrations in blood samples collected after an over-
night fast (see below). The subjects were also characterized with respect to their clini-
cal and biochemical features (Supplementary Table 3).  
 
All studies were conducted in accordance with the Declaration of Helsinki. Each par-
ticipant provided written informed consent after being explained the nature and poten-
tial risks of the study. The ethics committee of the Helsinki University Central Hospital 
approved the study protocol. 
 
Methods  
Liver fat (1H-MRS). In subjects not undergoing bariatric surgery (n=92), liver fat content 
was determined by proton magnetic resonance spectroscopy (1H-MRS) and the inten-
sity differences arising from various acquisition parameters and localization techniques 
were normalized as previously described  [28]. Liver fat content was expressed as a 
mass fraction  [29]. 
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Liver biopsies and histology. During bariatric surgery, wedge biopsies of the liver were 
obtained as described  [30]. Part of the biopsy was sent to the pathologist for histolog-
ical assessment. The rest of the biopsy was snap-frozen in liquid nitrogen for subse-
quent isolation of RNA and analysis of gene expression using qPCR (see below). Liver 
histology was analysed by an experienced liver pathologist in a blinded fashion as 
proposed by Brunt et al  [31]. NAFLD was diagnosed based on histology as macro-
scopic steatosis in >10% of hepatocytes  [32]. 
 
Subcutaneous adipose tissue biopsies. Needle biopsies of subcutaneous abdominal 
adipose tissue were obtained under local anaesthesia with 1% lidocain at the metabolic 
study visit, as previously described  [33]. The adipose tissue samples were immedi-
ately frozen in liquid nitrogen and stored at -80°C until analysis. 
 
Analysis of gene expression in adipose tissue and the liver. The relative mRNA con-
centrations of genes of interest in the liver and in the adipose tissue biopsies were 
quantified by qPCR. Total RNA was isolated from liver tissue by the RNeasy Mini Kit 
(Qiagen, Valencia, CA) and from subcutaneous adipose tissue by using the RNeasy 
Lipid Tissue Mini Kit (Qiagen). The RNA (500 ng) was reverse transcribed using the 
SuperScript VILO cDNA synthesis kit (Invitrogen, Carlsbad, CA). Each sample was 
amplified in duplicate for quantification of mRNA concentration of the coagulation fac-
tors (F8, F9, F11, F13A1, and FGG encoding FVIII, FIX, FXI, FXIII-A, and fibrinogen γ 
chain), pro-inflammatory (CD68, MCP-1, TNF-α) and anti-inflammatory (ADIPOQ en-
coding adiponectin, TWIST1) markers on a LightCycler® 480 (Roche Diagnostics, Rot-
kreuz, Switzerland) using the SYBR-Green kit (Roche Diagnostics). The hepatic ex-
pression of coagulation markers was normalized to that of the housekeeping gene 
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succinate dehydrogenase complex, subunit A (SDHA). The adipose tissue expression 
of inflammation markers was normalized to that of the housekeeping gene acidic ribo-
somal phosphoprotein 36B4 (36B4). Primer sequences are shown in Supplementary 
Table 4. 
 
Analytical procedures. Fasting plasma glucose was measured using a hexokinase 
method on an autoanalyser (Roche Diagnostics Hitachi 917, Hitachi Ltd., Tokyo, Ja-
pan). Fasting serum insulin concentrations were determined by time-resolved fluoro-
immunoassay using Insulin Kit (AUTOdelfia, Wallac, Turku, Finland). HbA1c was meas-
ured by high-pressure liquid chromatography using a fully automated Glycosylated He-
moglobin Analyzer System (BioRad, Richmond, CA). LDL and HDL cholesterol, and 
triglyceride concentrations were measured with respective enzymatic kits from Roche 
Diagnostics using an autoanalyzer (Roche Diagnostics Hitachi 917, Hitachi Ltd., To-
kyo, Japan). Serum creatinine, ALT and AST concentrations were determined as rec-
ommended by the European Committee for Clinical Laboratory Standards. Serum ad-
iponectin was measured using the Human Adiponectin ELISA kit from B-Bridge Inter-
national (Cupertino, CA) and serum MCP-1 using an ELISA kit from Quantikine, P&D 
Systems (Minneapolis, MN).  
 
Blood samples for coagulation assay were collected after an overnight fast from an 
antecubital vein into tubes containing 0.129 mol/l citrate. Plasma was separated by 
centrifugation for 20 min at 2245 g in room temperature, and frozen in aliquots that 
were stored at -70 ºC until assayed. Prothrombin time (PT, % of activity of normal), 
activated partial thromboplastin time (APTT, in seconds), and activities of fibrinogen, 
VWF, FVII, FVIII, FIX, FXI, FXII and FXIII were measured using the BCS® XP coagu-
lation analyser (Siemens Healthcare Diagnostics, Marburg, Germany) at the 
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coagulation laboratory of Helsinki University Hospital (HUSLAB) as previously de-
scribed  [15]. PT was measured with Owren method and the Nycotest® PT reagent 
(Axis-Shield, Oslo, Norway), APTT with the Actin® FSL reagent (Siemens Healthcare 
Diagnostics) and fibrinogen with a modification of the Clauss method (Multifibren® U; 
Siemens Healthcare Diagnostics). D-dimer was assessed using an immunoturbidimet-
ric assay (Tina-quant D-Dimer®, Roche Diagnostics, Mannheim, Germany). VWF 
ristocetin cofactor (VWF:RCo) activity was measured using the BC® von Willebrand 
Reagent, FVII activity using Dade® Innovin® and Coagulation Factor VII Deficient 
Plasma, and FXIII activity using Berichrom® FXIII, all the reagents from Siemens 
Healthcare Diagnostics. For one-stage FVIII, FIX, FXI and FXII activity measurements 
we used Pathromtin SL® and specific coagulation factor deficient plasma (all from Sie-
mens Healthcare Diagnostics). The local reference ranges were as follows: PT 70-130 
%, APTT 23-33 s, fibrinogen 1.7-4.0 g/l, D-dimer <0.5 mg/l, VWF:RCo 44-183 IU/dl 
(%), FVII 76-170 %, FVIII 52-148 %, FIX 67-135 %, FXI 60-120 %, FXII 60-150 % and 
FXIII 76-156 %.  
 
Statistical analyses. Distribution of continuous variables was tested for normality using 
the D’Agostino-Pearson normality test. Data are shown as mean ± SEM or, for non-
normally distributed data, as median followed by the 25th and 75th percentiles. Mean 
values between the groups were compared with the unpaired t-test and median with 
Mann-Whitney U test, or with the one-way analysis of variance and Kruskal-Wallis H 
test in the case of three or more groups. For categorical variables, Fisher’s exact test 
was used. We performed logarithmic transformation for non-normally distributed data 
when needed. Correlation analyses were performed using Pearson’s and Spearman’s 
correlation coefficient and partial correlation. The Grubbs’ test with an alpha-value 0.05 
was used to identify outliers that were then excluded. GraphPad Prism version 6.00 
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for Mac (GraphPad Software, San Diego, CA) and IBM SPSS Statistics 22.0 for Mac 
(IBM SPSS, Chicago, IL) were used to perform the statistical analyses. A p-value of 
less than 0.05 was considered statistically significant. 
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Results 
Subject characteristics and circulating coagulation factor activities  
The ‘IR’ and ‘IS’ groups were comparable with respect to age, gender and PNPLA3 
genotype (Table 1). Subjects in the ‘IR’ group had higher liver fat content (Figure 1A), 
fasting glucose and insulin, HOMA-IR, and triglyceride concentrations than the ‘IS’ 
group (Table 1). The PNPLA3148MM/MI group had greater liver fat content than the 
PNPLA3148II group (Figure 1A) but there were no differences in fasting glucose or in-
sulin, HOMA-IR or triglyceride concentrations between these groups (Table 1).  
 
Coagulation activities of FVIII (Figure 1B), FIX (Figure 1C), FXI (108 ± 2 vs. 96 ± 3%, 
p=0.001), FXII (111 ± 3 vs. 100 ± 4%, p=0.02), FXIII (105 ± 3 vs. 96 ± 3%, p=0.05), 
VWF:RCo (124 ± 7 vs. 99 ± 7%, p=0.01), the concentration of fibrinogen (4.2 ± 0.2 vs. 
3.6 ± 0.2 g/l, p=0.01) and PT (124 ± 3 vs. 114 ± 3%, p=0.01) were all significantly 
higher and APTT (Figure 1D) shorter in the ‘IR’ than the ‘IS’ group. Activities of FVII 
[118 (110-132) vs. 114% (100-129), p=0.18] and D-dimer concentrations [0.15 (0.05-
0.30) vs. 0.08 mg/l (0.05-0.20), p=0.20] did not differ between ‘IR’ and ‘IS’ groups. 
 
 
In contrast, all coagulation variables were comparable between the PNPLA3148MM/MI 
and PNPLA3148II groups: FVII [117 (97-128) vs. 117% (106-130), p=0.55], FVIII (Figure 
1B), FIX (Figure 1C), FXI (102 ± 3 vs. 103 ± 2%, p=0.86), FXII (105 ± 4 vs. 106 ± 3%, 
p=0.80), FXIII (104 ± 4 vs. 99 ± 3, p=0.29), fibrinogen (3.9 ± 0.2 vs. 4.0 ± 0.2 g/l, 
p=0.52), VWF:RCo (114 ± 7 vs. 110 ± 7 IU/dl, p=0.69), PT (121 ± 4 vs. 117 ± 2%, 
p=0.43), APTT (Figure 1D) and D-dimer [0.10 (0.05-0.30) vs. 0.10 mg/l (0.05-0.20), 
p=0.99], despite the liver fat distinction. 
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The degree of insulin resistance assessed by HOMA-IR correlated positively with ac-
tivities of FVII, FVIII, FIX, FXI, FXII, FXIII, VWF:RCo, fibrinogen and PT, and inversely 
with APTT. The relationships between HOMA-IR and activities of FVII, FVIII, FIX, FXI, 
FXII, VWF:RCo, PT and APTT remained significant after adjustment for age, gender, 
BMI and PNPLA3 genotype. Correlation coefficients and p-values are shown in Sup-
plementary Table 5.  
 
Characteristics of the subjects divided in a 2x2 fashion based on both the PNPLA3 
genotype and insulin sensitivity are shown in Supplementary Table 1. Activities of 
FVIII, FIX, FXI, fibrinogen and VWF:RCo were increased and APTT was shortened in 
IR as compared to IS subjects without the PNPLA3 gene variant (‘IR and PNPLA3148II’ 
vs. ‘IS and PNPLA3148II’, Supplementary Table 2). The PNPLA3 genotype did not in-
fluence the coagulation variables in either IS or IR subjects (Supplementary Table 2). 
 
Expression of F8, F9, FGG, F11 and F13A in the human liver 
Characteristics of the subjects lacking the PNPLA3 I148M gene variant who underwent 
a liver biopsy (n=26) are shown in Table 2. The subjects with ‘Metabolic NAFLD’ as 
compared to those without NAFLD had higher fasting serum insulin, HOMA-IR and 
plasma ALT, and lower Matsuda insulin sensitivity index (Table 2). The groups were 
equally obese and did not differ in age or gender. 
 
The gene expression of F8, F9 and FGG were higher in the ‘Metabolic NAFLD’ than in 
the ‘No NAFLD’ group (Figure 2). Expression of F11 (1.1 ± 0.1 vs. 1.0 ± 0.1, p=0.11) 
and F13A1 (1.2 ± 0.1 vs. 1.0 ± 0.1, p=0.28) did not differ between the ‘Metabolic 
NAFLD’ and ‘No NAFLD’ groups. 
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Relationship between coagulation factors activities and expression of pro- and anti-
inflammatory markers in adipose tissue and in serum in subjects lacking the PNPLA3 
I148M gene variant (PNPLA3148II) 
Characteristics of the subjects lacking the PNPLA3 I148M gene variant who underwent 
an adipose tissue biopsy are shown in Supplementary Table 3. Gene expression of 
the macrophage marker CD68 in adipose tissue correlated positively with PT % (Figure 
3A), FIX (Figure 3B), FXI (r=0.44, p<0.05) and VWF:RCo (r=0.40, p<0.05) activities, 
fibrinogen (Figure 3C), and D-dimer (r=0.59, p<0.01). Gene expression of MCP-1 cor-
related with FVIII (r=0.53, p<0.01), VWF:RCo (r=0.59, p<0.01) and D-dimer (r=0.60, 
p<0.01), and TNF-α with FIX (r=0.45, p<0.05) and FXI (r=0.47, p<0.05). Adipose tissue 
expression of the anti-inflammatory marker ADIPOQ correlated inversely with FIX (r=-
0.39, p<0.05) and fibrinogen (r=-0.41, p<0.05), and that of TWIST1 with the vitamin K-
dependent coagulation factors, PT % (r=-0.57, p<0.01) and FIX (r=-0.57, p<0.01) and 
with D-dimer (r=-0.48, p<0.01). Serum MCP-1 correlated positively with VWF:RCo 
(r=0.47, p=0.02) and serum adiponectin inversely with functional fibrinogen in plasma 
(r=-0.43, p=0.04).  
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Discussion 
In the present study, increased clotting activity characterized insulin-resistant subjects 
with increased liver fat compared to insulin-sensitive subjects. Subjects with the 
PNPLA3 I148M gene variant had a similar increase in liver fat as the insulin-resistant 
subjects in the absence of insulin resistance. Increases in liver fat were also accom-
panied by increases in serum AST and ALT. All coagulation variables were comparable 
between carriers and non-carriers of I148M variant, despite distinct amounts of fat in 
the liver. Subjects with ‘Metabolic NAFLD’, i.e. those who were lacking the I148M var-
iant but had insulin resistance and fatty liver, had clearly upregulated hepatic expres-
sion of F8, F9 and FGG compared to equally obese subjects without NAFLD. Thus, 
obesity does not explain increased coagulation factor expression in insulin-resistant 
subjects with NAFLD. In subjects lacking the PNPLA3 I148M gene variant, adipose 
tissue pro-inflammatory markers correlated positively and anti-inflammatory markers 
inversely with activities of FVIII, FIX, FXI, VWF:RCo and functional fibrinogen. These 
data demonstrate that insulin resistance rather than liver fat influences circulating co-
agulation factors and their susceptibility for activation. We suggest that adipose tissue 
inflammation and insulin resistance regulates FVIII, FIX and fibrinogen activities at the 
level of gene expression in the liver.  
 
Increased FVIII activity is associated with CVD  [34], insulin resistance  [35] and risk 
of venous thromboembolism  [36]. In the present study, activities of FVIII and its bind-
ing protein VWF were elevated in insulin-resistant subjects with increased liver fat but 
not in carriers of the PNPLA3 I148M variant with a compatible liver fat content. This 
shows that increased liver fat per se does not explain increased FVIII or VWF:RCo 
activities in humans. We also found, to our knowledge for the first time in human liver 
samples, that gene expression of F8, which encodes for FVIII, was upregulated in the 
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insulin-resistant subjects with increased liver fat compared to insulin-sensitive with nor-
mal liver fat (Fig. 2). FVIII is an acute phase protein, which is transcriptionally respon-
sive to NFκB activation by pro-inflammatory cytokines  [37]. The relationship between 
adipose tissue MCP-1 expression and FVIII activity supports the idea that adipose tis-
sue inflammation, systemic insulin resistance and hepatic acute-phase protein produc-
tion are closely interrelated  [9-11,38].  
 
FIX and FXI activities were increased in subjects with high liver fat content and insulin 
resistance, but not in PNPLA3 I148M variant carriers with high liver fat without insulin 
resistance. FIX  [39] and FXI  [40] are produced almost exclusively by the liver but their 
expression has not been compared between insulin-resistant and sensitive groups. We 
found the expression of F9 but not F11 to be upregulated in insulin-resistant subjects 
with ‘Metabolic NAFLD’ as compared to insulin-sensitive subjects without NAFLD. Sim-
ilarly to FVIII, FIX and FXI activities were closely correlated with the markers of inflam-
mation and adipokines in adipose tissue. Previous studies have reported circulating 
interleukin 6 and high-sensitive C-reactive protein, markers of low-grade inflammation 
in insulin-resistant subjects  [41], to correlate with the activities of FVIII, FIX, FXI, fi-
brinogen and VWF, and shortened prothrombin time  [42,43]. These data show that 
increased FIX and XI activities reflect obesity/insulin resistance rather than liver fat 
content per se, and that changes in FIX activity could reflect regulation of gene expres-
sion in the liver. However, regulation of FIX activity is complex  [44,45], and cannot be 
determined in a cross-sectional in vivo study.  
 
The liver is the main source of the inhibitory subunit B of FXIII  [46], while the active 
subunit A is expressed in liver, macrophages, monocytes and platelets  [47,48]. This 
together with the present data showing elevated FXIII activity but unchanged hepatic 
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expression of F13A1 in insulin-resistant subjects implies that FXIII activity is regulated 
via mechanisms other than those involving changes in hepatic F13A1 expression. 
 
The finding of increased fibrinogen concentration in insulin-resistant subjects with in-
creased liver fat is keeping with previous reports in obese subjects with NAFLD com-
pared to less obese subjects without NAFLD  [16]. We extend previous data by show-
ing that expression of fibrinogen, especially its γ chain, is upregulated in the liver of 
insulin-resistant subjects with ‘Metabolic NAFLD’ lacking the PNPLA3 gene variant. 
Consistent with the idea that the increase in fibrinogen gene expression could be a 
downstream event, reflecting inflammation in extra-hepatic tissues  [23], adipose tissue 
expression of the macrophage marker CD68 correlated positively and adiponectin in-
versely with functional fibrinogen in plasma.  
 
The extrinsic coagulation pathway including prothrombin, FVII and FX  [49] is triggered 
by tissue factor, which is closely associated with atherosclerotic plaques  [50]. PT 
measures the activity of this pathway, and APTT assesses the activity of the intrinsic 
coagulation pathway consisting of prothrombin, FV, VIII, IX, X, XI and XII, and fibrino-
gen  [12].  In the present study, subjects with increased liver fat and insulin resistance 
had shortened PT (i.e. % of normal was increased) and APTT, implying that the 
changes in individual coagulation factors indeed translated into a significantly en-
hanced clotting activity.  
 
Coagulation factor activities and insulin sensitivity were unchanged between subjects 
with and without PNPLA3 I148M variant, despite distinct liver fat contents. This finding 
accords with multiple studies showing that the PNPLA3 I148M gene variant predis-
poses to liver disease but not insulin resistance or risks of type 2 diabetes or CVD [2].  
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Taken together these data show that circulating coagulation factor activities are upreg-
ulated in subjects who have both an increased liver fat content and insulin resistance 
(‘Metabolic NAFLD’) but not in subjects who merely have an increased liver fat content 
due to the I148M PNPLA3 gene variant (‘PNPLA3 NAFLD’). Therefore, the patient who 
has ‘Metabolic NAFLD’ is likely to be at greater risk of thrombosis while the patient with 
‘PNPLA3 NAFLD’ is not at such risk.    
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What is known on this topic? 
• In non-alcoholic fatty liver disease (NAFLD), activities of coagulation factors are 
elevated. These changes may increase the risk of venous thrombosis and of ath-
erothrombotic vascular disease.  
• It is unknown whether the increment of coagulation factor activities in NAFLD is due 
to obesity/insulin resistance and associated adipose tissue inflammation or due to 
increased liver fat content per se. 
What this paper adds?  
• Clotting activity characterized insulin-resistant subjects with increased liver fat but 
not those with increased liver fat due to the PNPLA3 I148M variant. This indicates 
that obesity/insulin resistance rather than an increase in liver fat per se is associ-
ated with a procoagulant plasma profile. 
• Hepatic gene expression of coagulation factors FVIII, FIX and fibrinogen is upreg-
ulated in insulin-resistant subjects with NAFLD. 
• The degree of insulin resistance and adipose tissue inflammation correlate with 
activities of coagulation factors.  
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Table 1. Characteristics of the study groups. 
 IS 
(n=46) 
IR 
(n=46) 
PNPLA3148II 
(n=54) 
PNPLA3148MM/MI 
(n=38) 
HOMA-IR  1.0 (0.6-1.6) 3.6 (2.8-4.6) *** 2.4 (1.0-3.3) 2.4 (1.1-3.7) 
PNPLA3148II/PNPLA3148MM/MI 27/19 27/19 54/0 0/38 
     
Gender (men/women) 22/24 23/23 25/29 20/18 
Age (years) 40 (26-52) 43 (34-54) 40 (27-50) 43 (31-56) 
BMI (kg/m2) 28.2 ± 0.7 33.4 ± 0.6 *** 31.0 ± 0.7 30.5 ± 0.8 
Waist-to-hip ratio 0.91 ± 0.01 0.99 ± 0.01 *** 0.95 ± 0.01 0.95 ± 0.02 
Smoking status (current/ex-
smoker/never) 
4/0/42 6/0/40 5/0/49 5/0/33 
     
fS-insulin (mU/l) 4.2 (2.7-6.7) 14.1 (12.2-17.1)*** 10.4 (3.9-13.4) 8.8 (4.5-14.3) 
fP-glucose (mmol/l) 5.4 ± 0.1 5.7 ± 0.1 * 5.5 ± 0.1 5.6 ± 0.1 
HbA1c (%) 5.5 ± 0.1 5.7 ± 0.1 * 5.6 ± 0.1 5.6 ± 0.1 
fP-triglycerides (mmol/l) 1.0 (0.7-1.5) 1.6 (1.2-2.2) *** 1.3 (0.9-1.9) 1.2 (0.9-1.7) 
fP-HDL cholesterol (mmol/l) 1.5 (1.3-1.7) 1.3 (1.1-1.5) ** 1.4 (1.1-1.6) 1.3 (1.1-1.6) 
fP-LDL cholesterol (mmol/l) 2.9 (2.3-3.4) 3.1 (2.6-3.5) 2.9 (2.3-3.4) 3.0 (2.5-3.5) 
Leukocyte count (109 /l) 5.5 (4.7-6.6) 6.5 (5.7-7.3) ** 6.0 (5.0-7.0) 5.8 (5.0-7.2) 
     
P-AST (U/l) 25 (20-31) 30 (24-45) ** 25 (21-33) 31 (25-46) * 
P-ALT (U/l) 22 (17-46) 39 (24-81) *** 26 (19-53) 34 (19-80) 
P-AST/P-ALT  1.1 ± 0.1 0.8 ± 0.1 *** 0.9 ± 0.1 1.0 ± 0.1 
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Data are shown as mean ± SEM or median followed by the 25th and 75th percentile. 
*p<0.05, **p<0.005, ***p<0.0005. Abbreviations: ALT, alanine aminotransferase; AST, 
aspartate aminotransferase; BMI, body mass index; fP, fasting plasma; fS, fasting se-
rum; HbA1c, glycosylated hemoglobin A1c; HDL, high-density lipoprotein; HOMA-IR, 
homeostatic model assessment of insulin resistance; IR, insulin-resistant; IS, insulin-
sensitive; LDL, low-density lipoprotein; P, plasma. 
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Table 2. Characteristics of subjects undergoing liver biopsies. 
 No NAFLD 
(n=13) 
Metabolic NAFLD 
(n=13) 
HOMA-IR 1.7 (1.2-3.2) 4.6 (2.9-6.9) ** 
Matsuda ISI 79 (50-145) 35 (24-59) * 
PNPLA3148II/ PNPLA3148MM/MI 13/0 13/0 
   
Gender (men/women) 4/9 6/7 
Age (years) 44 ± 1 44 ± 2 
BMI (kg/m2) 45.7 ± 1.7 45.7 ± 0.9 
Waist circumference (cm) 130 ± 4 137 ± 4 
Waist-to-hip ratio 0.99 ± 0.04 1.02 ± 0.03 
Smoking status (current/ex-
smoker/never) 
3/5/5 3/4/6 
   
fP-glucose (mmol/l) 5.2 (4.7-5.9) 5.8 (5.3-6.2) 
fS-insulin (mU/l) 7.9 (5.5-12.5) 19.0 (12.1-26.6) * 
fS-C-peptide (nmol/l) 0.87 ± 0.09 1.41 ± 0.12 ** 
HbA1c (%) 5.7 ± 0.2 6.2 ± 0.2 
fP-triglycerides (mmol/l) 1.1 (0.8-2.1) 1.5 (1.2-2.0) 
fP-HDL cholesterol (mmol/l) 1.1 ± 0.1 1.0 ± 0.1 
   
Liver fat content (histology, %) 3.1 ± 1.2 45.8 ± 6.8 *** 
P-AST (U/l) 31 (25-39) 35 (28-41) 
P-ALT (U/l) 34 ± 3 52 ± 6 * 
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Data are shown as mean ± SEM or median followed by the 25th and 75th percentile. 
*p<0.05, **p<0.005, ***p<0.0005. Abbreviations: ALT, alanine aminotransferase; AST, 
aspartate aminotransferase; BMI, body mass index; fP, fasting plasma; fS, fasting se-
rum; HbA1c, glycosylated hemoglobin A1c; HDL, high-density lipoprotein; HOMA-IR, 
homeostasis model assessment of insulin resistance; ISI, insulin sensitivity index; LDL, 
low-density lipoprotein; NAFLD, non-alcoholic fatty liver disease; P, plasma. 
 
  
 33 
Figure legends 
Figure 1. Liver fat content (A), activities of FVIII (B) and FIX (C), and APTT (D) in 
insulin-sensitive (IS, n=46) vs. insulin-resistant (IR, n=46) group, and the PNPLA3148II 
(148II, n=54) vs. the PNPLA3148MM/MI (148MM/MI, n=38) group. Data are shown as 
mean ± SEM. *p<0.05 and ***p<0.0005. APTT, activated partial thromboplastin time; 
FIX, coagulation factor VIII; FIX, coagulation factor IX; 1H-MRS, proton magnetic res-
onance spectroscopy; P, plasma. 
 
Figure 2. Expression of F8, F9 and FGG relative to the housekeeping gene in the liver 
of subjects in ‘No NAFLD’ (white columns, n=13) and ‘Metabolic NAFLD’ (grey col-
umns, n=13) groups. Data are shown as mean ± SEM. *p<0.05 and **p<0.005. F8, 
coagulation factor VIII; F9, coagulation factor IX; FGG, fibrinogen g chain; NAFLD, non-
alcoholic fatty liver disease. 
 
Figure 3. Relationships (Pearson’s correlation coefficient) between PT (A), activity of 
FIX (B) and fibrinogen (C), and adipose tissue expression of CD68 in 26 non-bariatric 
subjects without the PNPLA3 I148M gene variant. PT, prothrombin time; FIX, coagu-
lation factor IX; P, plasma. 
